Study Type : Interventional (Clinical Trial)
Actual Enrollment : 32459 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants are assigned to one of two or more groups in parallel for the duration of the study.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Double Blind: two or more parties are unaware of the intervention assignment.
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Actual Study Start Date : August 28, 2020
Actual Primary Completion Date : March 5, 2021
Estimated Study Completion Date : February 24, 2023
Can you elaborate? What “vaccine” was this? Was there a control group? I see “placebo” mentioned. How can it be double blind if some get a placebo and yet had to function in a locked down society? Did they get a waiver for being a study participant?
I guess it is not over yet. I am very interested in seeing the results of this study, if being done by a reputable “firm” or group or university or what have you.
If properly done, THIS is what should have been done, with volunteers, before basically forcing it on the entire population.
And you can vouch for the veracity of this clinical trial’s data? Right?